Global Cancer/Tumor Profiling Market to Surge from USD 12.47 billion in 2024 to USD 26.29 billion by 2033 at 8.21% CAGR

The global cancer/tumor profiling market is witnessing robust growth, fueled by advancements in precision medicine and the increasing prevalence of cancer worldwide. Valued at USD 12.47 billion in 2024, the market is projected to reach USD 26.29 billion by 2033, growing at a CAGR of 8.21% during 2025-2033. Key drivers include the rising adoption of personalized treatment approaches, technological innovations in genomic and proteomic profiling, and the growing demand for biomarker-based diagnostics. North America currently leads the market, holding a significant share of over 42.8% in 2024 .
________________________________________
Study Assumption Years
• Base Year: 2024

• Historical Years: 2019-2024

• Forecast Years: 2025-2033

________________________________________
Cancer/Tumor Profiling Market Key Takeaways
• Market Size & Growth: The market was valued at USD 12.47 billion in 2024 and is expected to reach USD 26.29 billion by 2033, exhibiting a CAGR of 8.21% during 2025-2033 .

• Regional Dominance: North America holds the largest market share, accounting for over 42.8% in 2024, driven by advanced healthcare infrastructure and high adoption of precision medicine.

• Cancer Type Leadership: Breast cancer leads the market due to its high global prevalence and increasing adoption of personalized medicine in oncology.

• Technological Advancements: Next-Generation Sequencing (NGS) is a prominent technology, enabling comprehensive genomic analysis for identifying cancer mutations and biomarkers.

• Technique Utilization: Genomics is the largest technique segment, playing a central role in understanding the genetic basis of cancer.

• Application Focus: Personalized medicine is a significant application area, offering treatments based on individual genetic and molecular profiles.

• Emerging Markets: Asia Pacific is experiencing substantial growth due to rising cancer incidence and increasing adoption of advanced diagnostic technologies.
Request for a sample copy of this report : https://www.imarcgroup.com/cancer-tumor-profiling-market/requestsample
________________________________________
Market Growth Factors
1. Technological Advancements in Genomic and Proteomic : ProfilingTo a great extent, technological advances in genomic and proteomic profiling define the cancer/tumour profiling industry. With improvements in Next- Generation Sequencing (NGS), the ability to conduct complete genomic analyses has been changed, so enabling very exact identification of cancer mutations and markers. Individualized diagnoses and treatments made possible by these technologies therefore allow targeted therapies that improve patient outcomes. The demand for NGS in cancer profiling research is fueled by its increasing application in companion diagnostics as well as in clinical oncology.

2. Rising cancer incidence and desire for tailored therapy : The global increase in cancer incidence is one of the primary drivers of the growth of the market for cancer/tumor profiling. Better diagnosis and therapeutic options are much required given almost 20 million cases diagnosed worldwide in 2022 and predictions pointing towards a rise to 35 million by 2050. This tendency underscores the value of tumor profiling for developing customized therapies and increasing survival rates. The demand for sophisticated techniques in tumor profiling is fueled by the emphasis on accurate and sure diagnostic solutions toward enhancing patient outcomes.

3. Governmental Financing of Oncology Research : The market for cancer/tumor profiling will only develop with strong government backing and private investment in oncology research. Stressing the growing focus on innovation in cancer diagnostics and therapies, the UK Government has, for instance, pledged to boost its total research and development (RandD) budget to 2. 4% of GDP by 2027. By both increasing the accessibility of precision medicine and encouraging ground-breaking advancements in customized cancer treatment, these investments help the market grow.
.
________________________________________
Market Segmentation
By Cancer Type:
• Breast Cancer: Leads the market due to high global prevalence and increasing adoption of personalized medicine in oncology.

• Lung Cancer: Significant segment driven by the need for early detection and targeted therapies.

• Colorectal Cancer: Growing focus on early diagnosis and personalized treatment approaches.

• Prostate Cancer: Advancements in profiling techniques aiding in better management and treatment.

• Melanoma Cancer: Increasing utilization of tumor profiling for targeted therapy development.

• Others: Includes various other cancer types where profiling is becoming increasingly relevant.

By Technology:
• Next-Generation Sequencing (NGS): Enables comprehensive genomic analysis for identifying cancer mutations and biomarkers.

• Polymerase Chain Reaction (PCR): Highly sensitive and specific in detecting genetic mutations and alterations.

• Immunohistochemistry (IHC): Crucial for identifying biomarkers for targeted therapies, improving patient outcomes.

• In-Situ Hybridization (ISH): Valuable tool in oncology research and diagnostics for discovering therapeutic targets.

• Microarray: Facilitates the analysis of gene expression patterns and identification of biomarkers.

• Others: Includes various other technologies contributing to tumor profiling advancements.

By Technique:
• Genomics: Plays a central role in understanding the genetic basis of cancer, leading the market with around 39.8% share in 2024.

• Proteomics: Involves the large-scale study of proteins, essential for understanding cancer biology.

• Epigenetics: Focuses on heritable changes in gene expression without altering the DNA sequence, important in cancer development.

• Metabolomics: Studies metabolic changes in cancer cells, aiding in biomarker discovery and therapeutic targeting.

By Application:
• Personalized Medicine: Provides treatment based on an individual's genetic and molecular profile, improving therapy effectiveness.

• Diagnostics: Accurate identification of cancer type and stage via advanced tumor profiling techniques.

• Biomarker Discovery: Focuses on identifying molecular markers associated with cancer development and progression.

• Prognostics: Used to predict cancer progression, survival rate, and possible treatment response through tumor profiling.

• Others: Includes various other applications where tumor profiling is becoming increasingly relevant.

Breakup by Region:
• North America (United States, Canada)
• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa

________________________________________
Regional Insights
North America dominates the cancer/tumor profiling market, accounting for over 42.8% of the global share in 2024. This leadership is attributed to advanced healthcare infrastructure, high adoption of precision medicine, and substantial investments in oncology research. The region benefits from the widespread availability of advanced diagnostic technologies such as NGS and PCR, along with a strong presence of key market players. Rising cancer prevalence and government initiatives to support cancer screening and biomarker research further propel market growth .
________________________________________
Recent Developments & News
The cancer/tumor profiling market has seen several significant developments:
• In October 2024, Illumina partnered with AstraZeneca to develop innovative NGS-based companion diagnostics, enhancing oncology-related solutions.

• September 2024 saw Thermo Fisher launching the Oncomine Comprehensive Assay Plus, a targeted NGS tool designed to detect essential mutations in solid tumors.

• In November 2023, Illumina unveiled the latest version of its liquid biopsy assay for genomic profiling, the TruSight Oncology 500 ctDNA v2, providing comprehensive genomic insights from blood samples.

• May 2023 marked Pfizer's partnership with Thermo Fisher Scientific in a strategic collaboration aimed at increasing the availability of NGS-based testing for lung and breast cancer patients across more than 30 countries .

________________________________________
Key Players
• Abbott Laboratories
• Becton Dickinson and Company
• Caris Life Sciences
• Exact Sciences Corporation
• F. Hoffmann-La Roche Ltd
• Hologic Inc.
• HTG Molecular Diagnostics Inc.
• Illumina Inc.
• Laboratory Corporation of America Holdings
• NeoGenomics Laboratories
• Qiagen N.V.
• Siemens AG
• Sysmex Corporation

Ask Analyst for Customization: https://www.imarcgroup.com/request?type=report&id=5231&flag=C

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

Contact Us:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No: +1-631-791-1145

About Us:
IMARC Group is a global management consulting firm that helps the world's most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

This release was published on openPR.